GLP-1受体激动剂显著损害了味觉功能.
1Smell and Taste Center, Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
Physiology & behavior
|December 26, 2024
概括
常用于治疗肥胖症的葡萄糖类-1受体激动剂 (GLP-1RA),显著损害了味觉. 这项研究显示,使用这些流行的减肥药物的人口味觉功能显著下降.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 感官科学 感官科学
背景情况:
- 超过10%的美国人口使用类似葡萄糖-1受体激动剂 (GLP-1RA) 治疗肥胖.
- 虽然GLP-1RAs减少了食物的渴望,但它们对化学感官感知的影响仍然基本上未被探索.
研究的目的:
- 研究GLP-1RA对味觉和嗅觉功能的影响.
- 与对照组相比,在服用GLP-1RA的人群中量化化学感官知觉的任何变化.
主要方法:
- 使用了定量味道和气味测试:无水体实证味道测试 (WETT®) 和宾夕法尼亚大学气味识别测试 (UPSIT®).
- 评估了46名GLP-1RA患者和46名匹配对照,控制年龄,性别,吸烟和COVID-19病史.
- 分析数据使用差异分析来比较组之间的测试分数.
主要成果:
- GLP-1 RA使用者呈现显著下降的WETT®分数,表明味觉功能受损 (p < 0.001).
- 85%的GLP-1RA受试者在所有五个基本品味品质上比同等对照得分更差.
- 嗅觉功能 (UPSIT®) 显示轻微,非显著的下降 (p = 0.076);然而,像恶心这样的副作用与更好的感官得分相关.
结论:
- GLP-1RA显著改变味觉感知,这是第一次证明这一发现.
- 该机制可能涉及中枢神经系统的通路,包括脑干GLP-1受体和神经信号传递.
- 需要进一步的研究来阐明GLP-1RA诱导的味道变化的生理基础.
更多相关视频
09:31Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
Published on: November 9, 2018
8.6K
07:29Real-time Analysis of Gut-brain Neural Communication: Cortex wide Calcium Dynamics in Response to Intestinal Glucose Stimulation
Published on: December 29, 2023
593
相关概念视频
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
The Physiology of Taste
3.7K
The perception of a salty flavor is facilitated by sodium ions within the oral salivary fluid. Upon consumption of a salty substance, salt crystals disassemble, leading to the liberation of its constituents—Na+ and Cl- ions. These ions subsequently dissolve into the salivary fluid present in the oral cavity. The external environment of the gustatory cells experiences an elevation in Na+ concentration, thereby establishing a potent concentration gradient. This gradient propels the...
3.7K
Taste Buds and Receptors
1.8K
Gustation, or the sense of taste, is intrinsically linked to the anatomical structures located on the tongue. This organ's surface, along with the entirety of the oral cavity, is adorned with stratified squamous epithelium. Evident on the tongue are elevated structures known as papillae (singular = papilla), which house the mechanisms for the transduction of gustatory stimuli. Four distinct types of papillae exist, each identified by their unique morphological attributes: the circumvallate,...
1.8K
Gustation
47.6K
Gustation is a chemical sense that, along with olfaction (smell), contributes to our perception of taste. It starts with the activation of receptors by chemical compounds (tastants) dissolved in the saliva. The saliva and filiform papillae on the tongue distribute the tastants and increase their exposure to the taste receptors.
47.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
155
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
155
Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
